

## **Announcement Summary**

## **Entity name**

TELIX PHARMACEUTICALS LIMITED

#### Date of this announcement

Monday July 10, 2023

# The +securities the subject of this notification are:

€ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

# Total number of +securities to be issued/transferred

| ASX +security code | Security description      | Total number of<br>+securities to be<br>issued/transferred | Issue date |
|--------------------|---------------------------|--|------------|
| TLXAP              | SHARE RIGHTS              | 225,000  | 05/07/2023 |
| TLXAO              | SHARE APPRECIATION RIGHTS | 799,578  | 07/07/2023 |

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

# 1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

## 1.2 Registered number type

Registration number

ACN

616620369

### 1.3 ASX issuer code

TLX

## 1.4 The announcement is

☑ New announcement

#### 1.5 Date of this announcement

10/7/2023



#### Part 2 - Issue details

- 2.1 The +securities the subject of this notification are:
- € +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
- 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

### ASX +security code and description

TLXAO: SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

7/7/2023

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? 
⊗ No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Equity Incentive Plan Rules accessible at https://telixpharma.com/investor-centre/corporate-governance/

Any other information the entity wishes to provide about the +securities the subject of this notification

Performance Share Appreciation Rights (PSARs) granted to Telix employees as sign-on incentives. Performance metrics and material terms for PSARs issued during 2023 are detailed in Telix's 2022 Remuneration report, within its 2022 Annual Report accessible at <a href="https://telixpharma.com/investor-centre/financial-reports-presentations/">https://telixpharma.com/investor-centre/financial-reports-presentations/</a>

Issue details

Number of +securities

799.578

ASX +security code and description

**TLXAP: SHARE RIGHTS** 

Date the +securities the subject of this notification were issued

5/7/2023



Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? 
⊗ Yes

Provide details of the KMP or +associates being issued +securities.

| Name of KMP    | Name of registered holder | Number of +securities |
|----------------|---------------------------|-----------------------|
| Richard Valeix | Richard Valeix            | 35,000                |

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Equity Incentive Plan Rules accessible at https://telixpharma.com/investor-centre/corporate-governance/

Any other information the entity wishes to provide about the +securities the subject of this notification

Material terms for long-term incentive share rights issued during 2023 are detailed in Telix's 2022 Remuneration report, within its 2022 Annual Report accessible at <a href="https://telixpharma.com/investor-centre/financial-reports-presentations/">https://telixpharma.com/investor-centre/financial-reports-presentations/</a>

Issue details

Number of +securities

225,000



#### Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

## 4.1 Quoted +Securities (Total number of each +class of +securities quoted)

| ASX +security code and description | Total number of<br>+securities on issue |
|------------------------------------|---|
| TLX : ORDINARY FULLY PAID          | 318,557,198                             |

#### 4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

| ASX +security code and description                      | Total number of<br>+securities on issue |
|---|---|
| TLXAJ : OPTION EXPIRING 30-JUN-2024 EX \$1.83           | 1,300,000                               |
| TLXAI : OPTION EXPIRING 12-JAN-2024 EX \$2.23           | 1,460,000                               |
| TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL        | 80,000                                  |
| TLXAG : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 250,000                                 |
| TLXAP : SHARE RIGHTS                                    | 325,000                                 |
| TLXAO : SHARE APPRECIATION RIGHTS                       | 7,837,378                               |
| TLXAH : OPTION EXPIRING 03-NOV-2023 EX \$2.30           | 100,000                                 |
| TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37           | 809,992                                 |
| TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL        | 100,000                                 |
| TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38           | 1,089,099                               |



# Part 5 - Other Listing Rule requirements

- 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? 
  ☑ Yes
- 5.1a Select the number of the applicable exception in Listing Rule 7.2

13